Publicaciones en las que colabora con Miguel Gutiérrez Fraile (26)

2021

  1. The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design

    Revista de Psiquiatria y Salud Mental, Vol. 14, Núm. 3, pp. 164-176

  2. The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis

    Psychopharmacology, Vol. 238, Núm. 3, pp. 665-676

2020

  1. Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study

    Schizophrenia Research, Vol. 218, pp. 292-294

  2. Manual de trastornos adictivos

    J. Belarmino Bobes, M. Casas y M. Gutiérrez

  3. Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort

    Acta Psychiatrica Scandinavica, Vol. 141, Núm. 6, pp. 541-552

2018

  1. Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis

    Schizophrenia Research, Vol. 193, pp. 188-196

  2. Smoking does not impact social and non-social cognition in patients with first episode psychosis

    Schizophrenia Research, Vol. 199, pp. 64-74

2017

  1. Persistent negative symptoms in first-episode psychosis: Early cognitive and social functioning correlates and differences between early and adult onset

    Journal of Clinical Psychiatry, Vol. 78, Núm. 9, pp. 1414-1422

  2. The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study

    Schizophrenia Research, Vol. 189, pp. 84-90

2016

  1. Opposite cannabis-cognition associations in psychotic patients depending on family history

    PLoS ONE, Vol. 11, Núm. 8

2013

  1. Switching to ziprasidone in the clinical practice setting: An open-label study

    International Journal of Psychiatry in Medicine, Vol. 45, Núm. 2, pp. 125-142

2011

  1. Bupropion: efficacy and safety in the treatment of depression.

    Actas españolas de psiquiatría, Vol. 39 Suppl 1, pp. 1-25

  2. Manual de trastornos adictivos

    Enfoque

2005

  1. Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951

  2. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting

    Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486

2003

  1. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481

  2. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

    European Neuropsychopharmacology, Vol. 13, Núm. 1, pp. 39-48

2002

  1. Treatment of severely psychotic inpatients with schizophrenia: Olanzapine versus other antipsychotic drugs

    International Clinical Psychopharmacology, Vol. 17, Núm. 6, pp. 287-295

2001

  1. Abuso y dependencia de tóXIcos en pacientes psicóticos: tratados con risperidona. Disminución del consumo de cocaína y cannabis.

    Trastornos adictivos: Organo Oficial de la Sociedad española de Toxicomanías, Vol. 3, Núm. 4, pp. 289-290

  2. Efectividad y seguridad de risperidona a largo plazo en pacientes diagnosticados de esquizofrenia

    Psiquiatría biológica: Publicación oficial de la Sociedad Española de Psiquiatría Biológica, Vol. 8, Núm. 4, pp. 129-134